Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery

Conventional chemotherapy, one of the most widely used cancer treatment methods, has serious side effects, and usually results in cancer treatment failure. Drug resistance is one of the primary reasons for this failure. The most significant drawbacks of systemic chemotherapy are rapid clearance from...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2023-11, Vol.958, p.176013-176013, Article 176013
Hauptverfasser: Davodabadi, Fatemeh, Sajjadi, Seyedeh Fatemeh, Sarhadi, Mohammad, Mirghasemi, Shaghayegh, Nadali Hezaveh, Mahdieh, Khosravi, Samin, Kamali Andani, Mahdieh, Cordani, Marco, Basiri, Mohsen, Ghavami, Saeid
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Conventional chemotherapy, one of the most widely used cancer treatment methods, has serious side effects, and usually results in cancer treatment failure. Drug resistance is one of the primary reasons for this failure. The most significant drawbacks of systemic chemotherapy are rapid clearance from the circulation, the drug's low concentration in the tumor site, and considerable adverse effects outside the tumor. Several ways have been developed to boost neoplasm treatment efficacy and overcome medication resistance. In recent years, targeted drug delivery has become an essential therapeutic application. As more mechanisms of tumor treatment resistance are discovered, nanoparticles (NPs) are designed to target these pathways. Therefore, understanding the limitations and challenges of this technology is critical for nanocarrier evaluation. Nano-drugs have been increasingly employed in medicine, incorporating therapeutic applications for more precise and effective tumor diagnosis, therapy, and targeting. Many benefits of NP-based drug delivery systems in cancer treatment have been proven, including good pharmacokinetics, tumor cell-specific targeting, decreased side effects, and lessened drug resistance. As more mechanisms of tumor treatment resistance are discovered, NPs are designed to target these pathways. At the moment, this innovative technology has the potential to bring fresh insights into cancer therapy. Therefore, understanding the limitations and challenges of this technology is critical for nanocarrier evaluation. [Display omitted] •Drug resistance is one of the primary reasons for chemotherapy failure.•Nanoparticles-based drug delivery systems can overcome chemoresistance.•Nano-drugs improve pharmacokinetic & pharmacodynamic qualities of anticancer therapy.•Many nanocarriers targeting signaling pathways have been employed in clinical trials.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2023.176013